Homepage > Company > Media > Pharma News > 2019 > Israel's Healthy.io raises $60 million, gets FDA ok for urine test

Israel's Healthy.io raises $60 million, gets FDA ok for urine test

TEL AVIV (Reuters) - Israel’s Healthy.io said on Thursday it raised $60 million in funding and received clearance from the U.S. Food and Drug Administration for its smartphone-based urine albumin test to aid in diagnosing chronic kidney disease.

The funding round was led by Corner Ventures with participation by Joy Capital Ventures and previous investors Ansonia Holdings, Aleph and Samsung NEXT. The company has raised $95 million to date.

The funds will be used to accelerate Healthy.io’s global expansion and product development.

“The smartphone has the potential to be the great equalizer of healthcare,” said Yonatan Adiri, founder and CEO of Healthy.io.

This is the company’s second FDA clearance. Last year it received clearance for its at-home, smartphone-based urinalysis test kit and now has a partnership with Boots UK, placing its test kits in hundreds of pharmacies.

Sep 11, 2019

https://www.reuters.com/

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.